Effects of Some Antipsychotics and a Benzodiazepine Hypnotic on the Sleep-Wake Pattern in an Animal Model of Schizophrenia

Ishida, Takayuki; Obara, Yoshihito; Kamei, Chiaki

doi:10.1254/jphs.09142fp

Cited by 21 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aripiprazole significantly counteracted N-methyl D-aspartate (NMDA)-receptor antagonist-induced increased sleep latency [103]. With regards to antiepileptic activity, both seizureattenuating effects [93], as well as lack of such treatment effects were reported [104].…”

Section: Other Behavioral Alterationsmentioning

confidence: 99%

Aripiprazole in the treatment of Alzheimer's disease

Deyn

Drenth

Kremer

et al. 2013

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

In randomized placebo-controlled clinical trials, aripiprazole shows modest efficacy in the treatment of AD-related psychosis. Neuropsychiatric symptoms alleviated were predominantly psychotic features and agitation. In individual trials, aripiprazole was generally well tolerated, serious side effects were seldom reported and included accidental injury and somnolence. Meta-analyses however demonstrated increased mortality as a class effect for atypical, but also for typical antipsychotics. No increased cardiovascular outcomes, cerebrovascular accidents, increased appetite or weight gain were demonstrated in meta-analyses for aripiprazole-treated patients with psychosis of dementia. Aripiprazole was found to induce sedation. Aripiprazole should only be used in selected patient populations resistant to non-pharmacological treatment with persisting or severe psychotic symptoms and/or agitation, and in which symptoms lead to significant morbidity, patient suffering and potential self-harm. The indication for continuing treatment should be revised regularly.

show abstract

Section: Other Behavioral Alterationsmentioning

confidence: 99%

Aripiprazole in the treatment of Alzheimer's disease

Deyn

Drenth

Kremer

et al. 2013

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Clozapine and quetiapine are the most sedating [43] and the most likely to induce daytime somnolence. Drug combinations contribute to sedative load [44]. It is possible to develop a model that quantifies the cumulative effect of taking multiple drugs with sedative properties [45], often the reality for women with schizophrenia.…”

Section: Mechanism Of Antipsychotic-induced Sedationmentioning

confidence: 99%

Antipsychotic-Induced Somnolence in Mothers with Schizophrenia

Seeman

2011

Psychiatr Q

View full text Add to dashboard Cite

Although it is known that many antipsychotic drugs, at the doses prescribed for schizophrenia, are sedative and cause daytime drowsiness, the effect of potentially diminished vigilance on parenting parameters has not been studied. The aim of this paper is to advise clinicians about sedative load in mothers who are prescribed antipsychotic medication. A Medline search was conducted into the sedative effects of antipsychotics, with the following search terms: sleep; sedation; somnolence; wakefulness; antipsychotics; schizophrenia, parenting, maternal behavior, and custody. The results showed that antipsychotic drugs differ in their propensity to induce sedation and do so via their effects on a variety of neurotransmitter systems. It is important to note that mothers with schizophrenia risk losing custody of their infants if they are perceived as potentially neglectful because of excessive daytime sleepiness. Clinicians must choose antipsychotic medications carefully and monitor for sedative effects whenever the patient has important responsibilities that require the maintenance of vigilance.

show abstract

“…‹laç ve madde kötüye kullanm› veya ba¤›ml›l›¤› psikiyatri uygulama alan› içerisinde bulunmakta ve neredeyse tüm psikoaktif maddeler uyku-uyan›kl›k döngüsünü etkilemektedir (12,13). Bir di¤er sorun da psikiyatrik bozuklu¤u olanlar›n tedavisinde kullan›lan ilaçlar›n uyku üzerine etkilerinin olmas›d›r (14,15).…”

Section: Giriflunclassified

Akut Tam Uyku Yoksunluğunun Enerji Metabolizması Üzerine Etkileri

Çalıyurt¹,

Edis²,

Altıay³

2011

Npa

View full text Add to dashboard Cite

Objective: The aim of the present study was to assess the effects of total sleep deprivation on daily basal energy expenditure. Methods: Twenty healthy volunteers were included in the study. Resting energy expenditure was measured with indirect calorimetry device (Vmax 29c Sensor Medics, Yorba Linda, CA, USA) at 09:00 a.m., and food was withheld after midnight the prior evening. The measurements were carried out after eight hours of rest in awake subjects at constant ambient (environmental) temperature for at least 20 minutes. After 24 hours of total sleep deprivation, the measurements were repeated. Results: The first-measured mean resting energy expenditure was 1351.10±600.37 kcal/24 h and the second measurement revealed slight decrease with a mean value of 1250.60±454.39 kcal/24 h, but the difference did not reach the level of statistical significance. The changes in mean resting energy expenditure values before and after total sleep deprivation were evaluated in men and women separately, but no significant difference was observed between the two genders. Mean body mass index values correlated positively and significantly with both first and second resting energy measurements. Conclusion: Our results showed that total sleep deprivation did not directly affect daily basal energy expenditure. Sleep deprivation, sleep disorders and insomnia are associated with metabolic changes. Those metabolic effects are more likely related to chronic sleep restriction and changes in appetite and glucose metabolism that may cause weight gain and diabetes, rather than being direct effects on energy expenditure. (Archives of Neuropsychiatry 2011; 48: 17-21)

show abstract

Effects of Some Antipsychotics and a Benzodiazepine Hypnotic on the Sleep-Wake Pattern in an Animal Model of Schizophrenia

Cited by 21 publications

References 34 publications

Aripiprazole in the treatment of Alzheimer's disease

Aripiprazole in the treatment of Alzheimer's disease

Antipsychotic-Induced Somnolence in Mothers with Schizophrenia

Akut Tam Uyku Yoksunluğunun Enerji Metabolizması Üzerine Etkileri

Contact Info

Product

Resources

About